Table 4:
Characteristics of the five anti-HCV (–) patients who seroconverted to anti-HCV (+).
| Case No. | Site number | Age (years) | Sex | anti-HCV titer, S/CO | HCV RNA, IU/mLa | Original anti-HCV-seropositive rate in the local site, n/N (%) | Original HCV RNA seropositive rate in the local site, n/N (%) | Family history of HCV | Other potential risk behaviors between the two surveillances |
|---|---|---|---|---|---|---|---|---|---|
| #1 | No. 2 | 55 | M | 2.71 | <LLOD; <LLOD | 7/72 (9.7) | 4/72 (5.6) | No | Hospitalization for diabetic foot amputation |
| #2 | No. 2 | 61 | M | 9.17 | 0.099; recheck: 0.072 | 7/72 (9.7) | 4/72 (5.6) | No | No |
| #3 | No. 6 | 63 | M | 1.21 | <LLOD; <LLOD | 14/86 (16.3) | 10/86 (11.6) | No | No |
| #4 | No. 9 | 51 | F | 16.66 | 361.441; recheck: 177.065 | 11/50 (22.0) | 6/50 (12.0) | No | Dental procedure |
| #5 | No. 10 | 59 | M | 1.22 | <LLOD; <LLOD | 15/122 (12.3) | 7/122 (5.7) | No | No |
aRechecked 1 month apart for all patients.
M: male; F: female; LLOD: lower limit of detection, 12 IU/mL.